长春新碱硫酸盐
加载...长春新碱硫酸盐Recall
获取警报when a recall is issued.
问题和答案
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
目前尚无该药物可用的法律信息。
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
目前还没有生产informa的警告tion available for this drug.
FDA Labeling Changes
目前，该药物尚无FDA标签更改。
用途
急性白血病中表明硫酸盐注射硫酸盐。
硫酸盐注射还已被证明可与霍奇金氏病，非霍奇金的恶性淋巴瘤，横纹肌肉瘤，神经母细胞瘤和威尔姆斯肿瘤结合使用。
History
There is currently no drug history available for this drug.
其他信息
硫酸盐注射葡萄球菌，USP是从普通开花的草药（Periwinkle植物）获得的生物碱的盐（Vinca roseaLinn). Originally known as leurocristine, it has also been referred to as LCR and VCR.
硫酸盐硫酸盐的分子公式，USP为C46H56N4O10•H2SO4. It has a molecular weight of 923.04.
结构公式如下：
长春新碱硫酸盐, USP is a white to off–white powder. It is soluble in methanol, freely soluble in water, but only slightly soluble in 95% ethanol. In 98% ethanol, Vincristine Sulfate, USP has an ultraviolet spectrum with maxima at 221 nm (∈+47,100).
硫酸盐注射剂，USP是一种无菌，无防腐剂，仅一次性溶液，可用于2 mL（1 mg和2 mg）小瓶静脉内使用。每个ML含有1毫克硫酸盐，USP，100 mg甘露醇和水的注入，USP。Q.S.添加了硫酸或氢氧化钠以进行pH对照。硫酸盐注射的pH值为4.0至5.0。在制造时，容器中的空气被氮取代。
Sources
长春新碱硫酸盐制造商
-
Hospira Worldwide，Inc。
![长春新碱硫酸盐Injection, Solution [Hospira Worldwide, Inc.]](//www.lbxkm.com/wp-content/themes/bootstrap/assets/img/loading2.gif)
长春新碱硫酸盐|Hospira Worldwide，Inc。
This preparation is for intravenous use only (see WARNINGS).
Neurotoxicity appears to be dose related. Extreme care must be used in calculating and administering the dose of Vincristine Sulfate Injection, USP since overdosage may have a very serious or fatal outcome.
The usual dose of Vincristine Sulfate Injection, USP for pediatric patients is 1.5–2 mg/m2. For pediatric patients weighing 10 kg or less, the starting dose should be 0.05 mg/kg, administered once a week. The usual dose of Vincristine Sulfate Injection, USP for adults is 1.4 mg/m2. A 50% reduction in the dose of Vincristine Sulfate Injection, USP is recommended for patients having a direct serum bilirubin value above 3 mg/100 mL.
The drug is administered intravenously at weekly intervals.
为了减少由于不正确的给药途径而导致的致命药物错误的潜力，应在柔性塑料容器中稀释硫酸盐注射，并仅标记为静脉内使用（请参阅警告）。
The concentration of Vincristine Sulfate Injection, USP is 1 mg/mL. Do not add extra fluid to the vial prior to removal of the dose. Withdraw the solution of Vincristine Sulfate Injection, USP into an accurate dry syringe, measuring the dose carefully. Do not add extra fluid to the vial in an attempt to empty it completely.
Preparation for flexible plastic container
硫酸盐注射剂时，用0.9％氯化钠注射以0.0015 mg/ml至0.08 mg/ml的浓度稀释USP，可在24小时内稳定24小时或在25°C下的正常光线下进行8小时。
准备注射器
Special Dispensing Information: when dispensing Vincristine Sulfate Injection, USP in a syringe, it is imperative that it be packaged in the provided overwrap which bears the following statement: “DO NOT REMOVE COVERING UNTIL MOMENT OF INJECTION. FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES” (see WARNINGS). A syringe containing a specific dose must be labeled, using the auxiliary sticker provided, to state: “FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES.”
谨慎：在注射任何长春新碱之前，将静脉注射针或导管正确放置在非常重要的情况下。在静脉注射硫酸盐注射的静脉注射期间，渗入周围组织中，USP可能会引起很大的刺激。如果发生渗出，则应立即停止注射，然后将剂量的其余部分引入另一个静脉。局部注射透明质酸酶以及中等热量在泄漏区域的应用将有助于分散药物，并可能最大程度地减少不适感和蜂窝炎的可能性。
长春新碱硫酸盐Injection, USP must be administered via an intact, free–flowing intravenous needle or catheter. Care should be taken that there is no leakage or swelling occurring during administration (see boxed WARNINGS).
该溶液可以直接注射到静脉中，也可以被注入静脉输注的运行的管道（请参见下面的药物相互作用）。注射硫酸盐硫酸盐注射，应在1分钟内完成USP。
Patients Receiving Radiation Therapy - Vincristine Sulfate Injection, USP should not be given to patients while they are receiving radiation therapy through ports that include the liver. When Vincristine Sulfate Injection, USP is used in combination with L–asparaginase, Vincristine Sulfate Injection, USP should be given 12 to 24 hours before administration of the enzyme in order to minimize toxicity; administering L–asparaginase before Vincristine Sulfate Injection, USP may reduce hepatic clearance of vincristine.
药物相互作用 - 硫酸盐注射，USP不应稀释在3.5至5.5范围内的pH值或降低pH值的溶液中。它不应与普通盐水或水中的葡萄糖之外的任何东西混合。
Whenever solution and container permit, parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.
处理和处置 - 应考虑适当处理和处置抗癌药物的程序。1已发表了有关该beplay体验主题的几项准则。1尚未达成一般协议，即准则中建议的所有程序都是必要或适当的。
登录到您的免费帐户